Characteristics of Long-Term Survivors With EGFR-Mutant Metastatic NSCLC-Reference-Cited by-同舟云学术

Characteristics of Long-Term Survivors With EGFR-Mutant Metastatic NSCLC

Published:2024-08 Issue:8 Volume:5 Page:100669
ISSN:2666-3643
Container-title:JTO Clinical and Research Reports
language:en
Short-container-title:JTO Clinical and Research Reports

Author:

Tompkins William,Grady Connor B.,Hwang Wei-Ting,Chandrasekhara Krishna,McCoach Caroline,Sun Fangdi,Liu Geoffrey,Patel Devalben,Nieva Jorge,Herrmann Amanda,Marrone Kristen,Lam Vincent K.,Velcheti Vamsi,Liu Stephen V.,Montenegro Gabriela Liliana Bravo,Patil Tejas,Weiss Jared,Miller Kelsey Leigh,Schwartzman William,Dowell Jonathan E.,Shaverdashvili Khvaramze,Villaruz Liza,Cass Amanda,Iams Wade,Aisner Dara,Aggarwal Charu,Camidge D. Ross,Marmarelis Melina E.,Sun Lova

Funder

AstraZeneca

LUNGevity Foundation

AACR

Publisher

Elsevier BV

Reference35 articles.

1. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study;Zhou;Lancet Oncol,2011

2. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial;Rosell;Lancet Oncol,2012

3. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009

4. Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR;Maemondo;N Engl J Med,2010

5. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial;Mitsudomi;Lancet Oncol,2010